Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study (NCT04008030) of first-line nivolumab plus ipilimumab versus chemotherapy for patients with MSI-H/dMMR metastatic colorectal cancer (mCRC). Nivolumab and ipilimumab showed improved time to second objective disease progression (PFS2) and manageable safety profiles, reinforcing its role as a standard first-line treatment for MSI-H/dMMR mCRC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
